Puma Biotech (PBYI) Tops Q3 EPS by 10c; Offers FY23 Revenue Guidance

Puma Biotech (NASDAQ: PBYI) reported Q3 EPS of $0.18, $0.10 better than the analyst estimate of $0.08. Revenue for the quarter came in at $56.1 million versus the consensus estimate of $57.95 million.

GUIDANCE:

Puma Biotech sees FY2023 revenue of $206-209 million, versus the consensus of $236.2 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM